Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2018-09-20
DOI
10.1080/2162402x.2018.1512329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
- (2017) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Oncolytic Maraba Virus MG1 as a Treatment for Sarcoma
- (2017) Fabrice Le Boeuf et al. INTERNATIONAL JOURNAL OF CANCER
- Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
- (2017) Yong-Chen Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Ever CAR T-cell Therapy Approved in U.S.
- (2017) Cancer Discovery
- NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine
- (2017) Almohanad A. Alkayyal et al. Cancer Immunology Research
- Customized Viral Immunotherapy for HPV-Associated Cancer
- (2017) Matthew J. Atherton et al. Cancer Immunology Research
- Oncolytic Viruses in Cancer Treatment
- (2017) Sean E. Lawler et al. JAMA Oncology
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies
- (2016) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination
- (2016) Byram W. Bridle et al. JOURNAL OF IMMUNOLOGY
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic cancer/testis antigens: prime candidates for immunotherapy
- (2015) Morten F. Gjerstorff et al. Oncotarget
- Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment
- (2015) Kirsten Ridder et al. OncoImmunology
- First oncolytic virus approved for melanoma immunotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- Trial Watch—Immunostimulation with cytokines in cancer therapy
- (2015) Erika Vacchelli et al. OncoImmunology
- Trial Watch—Oncolytic viruses and cancer therapy
- (2015) Jonathan Pol et al. OncoImmunology
- Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis
- (2015) Jessica G Tong et al. Molecular Therapy-Oncolytics
- Maraba MG1 Virus Enhances Natural Killer Cell Function via Conventional Dendritic Cells to Reduce Postoperative Metastatic Disease
- (2014) Jiqing Zhang et al. MOLECULAR THERAPY
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Trial watch: Dendritic cell-based anticancer therapy
- (2014) Norma Bloy et al. OncoImmunology
- Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
- (2013) Richard A. Morgan et al. JOURNAL OF IMMUNOTHERAPY
- Functional Cloning of Recurrence-specific Antigens Identifies Molecular Targets to Treat Tumor Relapse
- (2013) Nicolas Boisgerault et al. MOLECULAR THERAPY
- Maraba Virus as a Potent Oncolytic Vaccine Vector
- (2013) Jonathan G Pol et al. MOLECULAR THERAPY
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
- (2013) Charles G. Drake et al. Nature Reviews Clinical Oncology
- Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+T-cell responses to anticancer vaccines
- (2013) Byram W Bridle et al. OncoImmunology
- Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-cell Transfer
- (2012) D. M. Rommelfanger et al. CANCER RESEARCH
- Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses
- (2012) D. J. Mahoney et al. CLINICAL CANCER RESEARCH
- Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
- (2012) Jose Pulido et al. NATURE BIOTECHNOLOGY
- Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates
- (2012) Chad E. Mire et al. PLoS Neglected Tropical Diseases
- Tumor-infiltrating B cells and T cells
- (2012) Julie S. Nielsen et al. OncoImmunology
- Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death
- (2011) Douglas J. Mahoney et al. CANCER CELL
- Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
- (2011) Timothy Kottke et al. NATURE MEDICINE
- The role of non-human primates in the neurological safety of live viral vaccines (review)
- (2010) Inessa Levenbook BIOLOGICALS
- Potentiating Cancer Immunotherapy Using an Oncolytic Virus
- (2010) Byram W Bridle et al. MOLECULAR THERAPY
- Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
- (2010) Jan Brun et al. MOLECULAR THERAPY
- Personalized vaccines: the emerging field of vaccinomics
- (2008) Gregory A Poland et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now